Clinical trials: Hospitalizations
Heart Failure
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)
The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart…
- Trial name
- NCT01300013
- Testing
- Omecamtiv mecarbil
- Where
- 150 sites in United States, Australia and 17 more
- Volunteers
- 614 people
- Sponsor
- Cytokinetics
Heart Failure
Voice Analysis for Monitoring Patients With Heart Failure
This observational study involves ADHF patients at two sites in the United States and Germany. After informed consent and screening assessments, participants will perform daily voice recordings during their hospital stay, from…
- Trial name
- VAMP-HF (NCT06566911)
- Where
- 2 sites in United States, Germany
- Volunteers
- 70 people
- Sponsor
- Noah Labs
Bacterial Infections
Study Evaluating Zosyn in Hospitalized Patients With Intra-abdominal Infection
A Phase IV, multicenter study of hospitalized patients with complicated intra-abdominal infection.
- Trial name
- NCT00044928
- Testing
- Piperacillin/Tazobactam
- Volunteers
- 262 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
COVID-19
Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)
This study is a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of FB2001 in hospitalized patients with moderate to severe Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT05445934
- Testing
- FB2001
- Where
- 2 sites in China
- Volunteers
- 1,188 people
- Sponsor
- Frontier Biotechnologies Inc.
Diabetes Mellitus, Type 2
Risk of Hospitalized Infections Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatment
The purpose of this study is to compare the incidence of hospitalizations for infections among patients with type 2 diabetes mellitus who are new initiators of Saxagliptin and those who are new initiators of Oral Anti-Diabetic…
- Trial name
- NCT01086306
- Volunteers
- 113,505 people
- Sponsor
- AstraZeneca
Pneumonia, Bacterial, Community-Acquired Infections
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
The purpose of this study is to evaluate the safety and tolerability of doripenem compared to cefepime in children hospitalized with pneumonia.
- Conditions
- Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
- Trial name
- NCT01110421
- Testing
- Cefepime, Doripenem, Amoxicillin/clavulanate potassium
- Where
- 25 sites in United States, Argentina and 8 more
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC
Coronavirus Disease 2019 (COVID-19)
Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.
A randomized, open-label, multicenter, three-arm clinical trial to study the efficacy and safety of passive immunotherapy (convalescent plasma and anti-COVID-19 human immunoglobulin) compared to the standard treatment in Colombia.
- Trial name
- NCT04395170
- Testing
- COVID-19 convalescent plasma, Anti-COVID-19 human immunoglobulin, Standard (specific) therapy for COVID-19
- Where
- Colombia
- Volunteers
- 75 people
- Sponsor
- Lifefactors Zona Franca, SAS
COVID-19 Infection
An Open-Label Study of Apabetalone in Covid Infection
The primary objective of the study is to evaluate the safety and effect on clinical course of oral apabetalone in hospitalized subjects with Covid-19 infection
- Trial name
- NCT04894266
- Testing
- Apabetalone, Standard of care
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Resverlogix Corp
Covid19, Corona Virus Infection
A Study of Baricitinib (LY3009104) in Children With COVID-19
The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.
- Trial name
- COV-BARRIER (NCT05074420)
- Testing
- Baricitinib
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 6 people
- Sponsor
- Eli Lilly and Company
COVID-19, Severe Respiratory Distress Syndrome
suPAR Michigan M2C2 Heterogeneity Validation Cohort Study
This is a retrospective, non interventional cohort study using stored plasma samples from appoximately 300 adults hospitalized with confirmed COVID 19.
- Conditions
- COVID-19, Severe Respiratory Distress Syndrome, Acute Respiratory Distress Syndrome
- Trial name
- NCT07466524
- Testing
- suPARnostic® TurbiLatex Assay on Roche cobas c501
- Where
- United States
- Volunteers
- 367 people
- Sponsor
- ViroGates A/S
Schizophrenia
A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
A Phase 3, Multicenter, Two-part Study with a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) followed by a 12-week Open-label Extension Part, to Evaluate the Efficacy and Safety of KarXT in Acutely…
- Trial name
- UNITE-001 (NCT05919823)
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 28 sites in China
- Volunteers
- 202 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
COVID-19
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
The study will evaluate the efficacy and safety of aprepitant injectable emulsion added to standard of care for hospitalized patients with COVID-19.
- Trial name
- NCT04470622
- Testing
- Aprepitant injectable emulsion
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Heron Therapeutics
Costs and Cost Analysis, Effectiveness
Hospital at Home Versus Inpatient Care: Costs and Effectiveness
Background and Objectives Hospital at Home (HaH) delivers hospital-level treatment to acutely ill patients in their own homes, including daily medical and nursing visits, infusions, physiotherapy, and diagnostics.
- Conditions
- Costs and Cost Analysis, Effectiveness, Patient Satisfaction
- Trial name
- NCT07274072
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- Hospital at Home AG
COVID-19
A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
The study assessed the efficacy and safety of Brilacidin for the treatment of COVID-19 in hospitalized participants
- Trial name
- NCT04784897
- Testing
- Brilacidin, Standard of Care (SoC)
- Where
- 12 sites in United States, Russia
- Volunteers
- 120 people
- Sponsor
- Innovation Pharmaceuticals, Inc.
Hypercholesterolemia, Acute Coronary Syndrome
Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia
Primary Objective: To compare the efficacy of alirocumab (Praluent®) with standard of care (SoC) on coronary atheroma progression (percent change in normalized total atheroma volume [TAV]) after 9 months of treatment in…
- Trial name
- ODYSSEY J-IVUS (NCT02984982)
- Testing
- Alirocumab SAR236553, Atorvastatin, Rosuvastatin
- Where
- 39 sites in Japan
- Volunteers
- 206 people
- Sponsor
- Sanofi
covid19
Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19
This is a pivotal phase III study to evaluate the efficacy of nitazoxanide 600 mg BID compared to placebo to treat hospitalized patients with non-critical COVID-19.
- Trial name
- NCT04423861
- Testing
- Nitazoxanide
- Where
- Brazil
- Volunteers
- 380 people
- Sponsor
- Azidus Brasil
Major Depressive Disorder With Suicidal Ideation With Intent
Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent
Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder (MDD) in subjects who have suicidal ideation with intent
- Trial name
- NCT04722666
- Testing
- MIJ821 Intravenous Injection
- Where
- 39 sites in United States, Argentina and 12 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Respiratory Syncytial Virus Lower Respiratory Tract Infection
Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection
The primary objective is to evaluate the anti-viral effect and safety of different doses of inhaled ALX-0171 in subjects hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection (RSV LRTI).
- Trial name
- Respire (NCT02979431)
- Testing
- ALX-0171 3.0 mg/kg, ALX-0171 6.0 mg/kg, ALX-0171 9.0 mg/kg
- Where
- 74 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 180 people
- Sponsor
- Ablynx, a Sanofi company
Skin Diseases, Infectious
Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cSSSI
Tigecycline's activity against resistant organisms, as well as significant coverage of both gram-positive and gram-negative bacteria, may provide a valuable therapeutic alternative in treating patients with complicated skin…
- Trial name
- NCT00488761
- Testing
- Tigecycline
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Osteonecrosis of the Jaw, Infection Leading to Hospitalization
Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid
A non-interventional study to assess incident rates of Osteonecrosis of the Jaw and Infections leading to hospitalization in Cancer patients treated with XGEVA™ in Sweden, Denmark and Norway.
- Trial name
- NCT01967160
- Volunteers
- 2,560 people
- Sponsor
- Amgen